RenovoRx, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. Filed March 29, 2022.
Business context
RenovoRx is a clinical-stage biopharmaceutical company with no approved drug/device combination products and no product-sales revenue. Its lead candidate, RenovoGem, combines intra-arterial gemcitabine with the RenovoCath delivery system, using the RenovoTAMP platform to deliver chemotherapy locally to solid tumors. The company’s lead program is the TIGeR-PaC Phase 3 trial in locally advanced pancreatic cancer (LAPC); it also planned a Phase 2 study in extrahepatic cholangiocarcinoma (eCCA). RenovoCath has FDA device clearances, but RenovoGem remains investigational and requires drug approval.
Key financial metrics
| Metric | FY2021 / December 31, 2021 | FY2020 / December 31, 2020 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $3.039 million | $2.386 million |
| General and administrative expense | $2.632 million | $0.818 million |
| Total operating expenses / operating loss | $5.671 million / $(5.671) million | $3.204 million / $(3.204) million |
| Net loss | $(6.324) million | $(3.798) million |
| Net loss per share, basic and diluted | $(1.21) | $(1.72) |
| Net cash used in operating activities | $(5.916) million | $(3.528) million |
| Cash and cash equivalents | $15.192 million | $1.795 million |
| Total assets / total liabilities | $16.287 million / $0.938 million | $1.914 million / $4.119 million |
| Accumulated deficit | $(21.284) million | $(14.960) million |
Gross profit and operating margins are not meaningful because the company had no product-sales revenue. Current assets were $16.281 million and current liabilities $0.938 million at year-end; the balance-sheet components imply working capital of approximately $15.343 million. Management separately described cash and working capital as approximately $15.2 million.
Cash provided by financing activities was $19.328 million, primarily from the IPO, convertible-note proceeds and warrant exercises; investing activities used $15,000. The $5.0 million of 2020 and 2021 convertible notes, plus accrued interest, converted into equity units upon the August 2021 IPO. No convertible notes or derivative liability remained at year-end. The company reported no material contractual obligations or commitments as of the report date, apart from its ordinary lease and operating arrangements.
Changes versus FY2020
- Net loss increased by $2.526 million, or 67%; total operating expenses rose 77%. R&D increased 27%, while G&A rose 222%, largely reflecting public-company costs, IPO-related and post-IPO professional services, and D&O insurance.
- Operating cash use increased by $2.388 million. Year-end cash rose by $13.397 million, chiefly reflecting IPO financing and warrant exercises.
- RenovoRx completed its IPO in August 2021, receiving $14.6 million net proceeds. Preferred stock converted to common stock, and convertible notes converted into common shares and warrants.
- The 2020 audit report included a going-concern explanatory paragraph. The 2021 auditor gave an unqualified opinion on the financial statements; management said year-end cash was expected to fund the plan for at least 12 months from issuance, and elsewhere said through at least the next 12 months and into 2023, assuming programs advance as planned.
Outlook, commentary and risks
- Management expects continued operating losses, negative operating cash flow and rising R&D and G&A expenses. It said additional funding will be needed to complete development and commercialization; financing may be unavailable or costly, and could dilute shareholders or constrain operations.
- As of March 15, 2022, TIGeR-PaC had reached approximately 50% of target enrollment under the current statistical analysis plan. The company expected an interim analysis after 65 deaths, with timing estimated between Q4 2022 and Q1 2023, and projected completion of enrollment and randomization in 2023. Timing depends on trial events and is uncertain.
- In December 2021, the company closed its Belgium trial sites because of enrollment challenges, including COVID-related recruiting issues and differences in standard of care affecting eligibility. It also amended TIGeR-PaC to permit SBRT, but not IMRT, during induction; management cited higher dropout with the longer IMRT regimen.
- The planned eCCA Phase 2 protocol was still being refined. The company planned to discuss trial design with FDA in Q2 or Q3 2022 and anticipated a second-half 2022 start only if FDA did not object. Orphan Drug Designations for pancreatic cancer and cholangiocarcinoma are not marketing approvals; potential seven-year exclusivity depends on approval and other conditions.
- Early RR1/RR2 studies reported favorable survival signals in selected patients, including median overall survival of 27.9 months in a prior-radiation subgroup. These were small, nonrandomized or observational studies, and prior standard-of-care treatment was not prospectively controlled; the results are not directly comparable to randomized historical trials. The Phase 3 trial is intended to test efficacy against standard of care.
- Key risks include trial failure or delay, patient-enrollment and COVID-related disruption, regulatory uncertainty, need for additional capital, reliance on third parties and a single-source RenovoCath manufacturer, competition, reimbursement uncertainty, and intellectual-property challenges.
- Management reported material weaknesses in internal control over financial reporting, including insufficient accounting expertise and staffing, inadequate written policies and review controls, and insufficient segregation of duties. Disclosure controls were considered ineffective. The company said it was implementing remediation measures and expected to complete the plan during 2022; effectiveness had not yet been established.
Most important facts for investors to verify
- Current cash runway, actual spending and financing needs against the clinical-development plan.
- TIGeR-PaC enrollment progress, protocol implementation, interim-analysis timing and eventual randomized efficacy and safety results.
- Whether the eCCA protocol receives FDA feedback sufficient to proceed, and whether the anticipated trial start occurs.
- Progress in remediating the disclosed material weaknesses and whether subsequent filings report effective controls.
- RenovoCath supply continuity and qualification of an alternative manufacturer, alongside the regulatory and reimbursement pathway for RenovoGem.